Participated · Equity · Oct 2025

Milan-based Cyberwave provides an operating layer that connects AI agents to physical machines by abstracting robots, sensors, and actuators into digital twins. Its catalogue of twins works as a two-sided marketplace: hardware makers integrate once, and developers then gain plug-and-play access to a growing library of industrial arms, drones, cameras, and other devices. This architecture allows engineers to simulate, control, and orchestrate heterogeneous machines with far less effort than traditional bespoke integrations, addressing high integration costs that keep roughly 30 % of manufacturing tasks manual. Early pilots are running with major European manufacturers in automotive, construction, and logistics, covering use cases like assembly-line defect rework, warehouse packing optimisation, drone inspections, and smart-camera upgrades. The company intends to launch the platform publicly in October 2025, expand its developer ecosystem, and validate enterprise deployments. While currently focused on Europe, Cyberwave plans a U.S. presence to support customers’ overseas sites and to tap North American re-industrialisation trends. Co-founders Simone Di Somma and Vittorio Banfi position the company as the “system of actions” for the physical world, analogous to SAP’s role in digital processes.

Participated · Seed · Jul 2024

Intron Health builds clinical speech-recognition technology tailored to African accents and medical vocabulary, and can integrate with existing EMRs. Its algorithm is trained on 3.5 million audio clips (16,000 hours) from over 18,000 contributors across 29 countries and 288 accents, primarily from healthcare practitioners. The tool is live in 30 hospitals across five markets, including deployments in Kenya and Nigeria, and has been shown to cut radiology-result wait times in one West African hospital from 48 hours to 20 minutes. The company plans technical improvements including better noise cancellation, low-bandwidth performance, multi-speaker transcription and text-to-speech, and aims to add decision-support/clinical-intelligence tools for prescriptions and lab tests. Intron was launched in 2020 and is also engaged in speech-research partnerships with Google Research, the Bill & Melinda Gates Foundation, and Digital Square at PATH to evaluate LLMs across 15 countries. The startup raised a $1.6 million pre-seed round to support product development and expansion.

Participated · Seed · Dec 2021

Sixfold Bioscience develops the Mergo® RNA therapeutics delivery platform, combining computational screening, high-throughput chemistry, and iterative testing to identify biocompatible building blocks that target selected cell types. The platform is focused on short interfering RNA for gene silencing and messenger RNA for gene expression. Mergo’s modular building-block approach aims to modulate pharmacokinetics and pharmacodynamics to expand RNA therapeutics beyond the liver and local administration. The company leads a series of collaborations on RNA therapeutics and has received non-dilutive support tied to that work. Sixfold was founded in 2017 by Dr George Foot and Dr Perdrix Rosell and operates from London. The recent financing will support continued R&D and expansion of the platform across several therapeutic indications.

Led · Seed · Mar 2021

Allelica builds fast, efficient and scalable software to implement clinically accessible polygenic risk scores (PRSs). Its technology combines large datasets and advanced algorithms to generate PRSs for diseases including coronary artery disease, breast, prostate and colon cancers, Type 2 diabetes and Alzheimer’s disease. Allelica’s tools aim to translate genomic data into practical risk‑stratification used for preventative medicine and early intervention. The company cites a publication in Circulation showing how its PRS for coronary artery disease can alter clinical risk assessments tied to LDL cholesterol. Allelica has commercial traction, including several customers and a partnership with Merck to develop cardiovascular disease prevention tools. The company recently raised seed financing to advance clinical integration of its PRS software into US healthcare systems and relocated its headquarters to New York City.

Participated · Series A · Jul 2020

InSilicoTrials offers a cloud-based catalogue of simulation models and tools designed for clinical trials of drugs and medical devices. The platform turns mathematical models into user-friendly tools and operates a secure cloud network, working with researchers, regulatory agencies and universities worldwide. Founded in 2017 and based in Trieste, the company says its pay-per-use model democratises access to simulation software for smaller players as well as market leaders. The startup cites a reach of over 52,000 medical and 3,200 pharmaceutical companies for its offering. Company leadership frames the technology as a way to accelerate clinical research, support personalised medicine and enable complex surgical planning and 3D-printed prostheses. Market research referenced in the article projects the global biosimulation market will exceed $4.5 billion in the next five years, underpinning demand for the product.